Neumora Therapeutics, Inc.
NMRAAs of the close on Sep 25, 2026
Price
$0.68
Market cap
$127M
P/E (diluted TTM)
—
Not meaningful: the last four quarters were a loss
EPS (TTM)
−$1.23
Four quarters to Jun 30, 2026
Dividend yield
—
Dividend records do not yet cover the latest payments
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How Neumora Therapeutics, Inc. Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 4 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated May 29, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Atom Investors LP | 2026-03-31 | 23,755 | Not shown | SEC filing |
| SBI Securities Co., Ltd. | 2026-03-31 | 18 | Not shown | SEC filing |
| GOLDMAN SACHS GROUP INC | 2026-03-31 | 568,280 | Not shown | SEC filing |
| HSBC HOLDINGS PLC | 2026-03-31 | 11,387 | Not shown | SEC filing |
| Addis & Hill, Inc | 2026-03-31 | 163,386 | Not shown | SEC filing |
| Centerpoint Advisors, LLC | 2026-03-31 | 220 | Not shown | SEC filing |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 2026-03-31 | 225,000 | Not shown | SEC filing |
| Meridian Wealth Management, LLC | 2026-03-31 | 102,400 | Not shown | SEC filing |
| FMR LLC | 2026-03-31 | 3,498,658 | Not shown | SEC filing |
| HBK Sorce Advisory LLC | 2026-03-31 | 17,037 | Not shown | SEC filing |
| Physician Wealth Advisors, Inc. | 2026-03-31 | 1,320 | Not shown | SEC filing |
| JPMORGAN CHASE & CO | 2026-03-31 | 274,103 | Not shown | SEC filing |
| Tower Research Capital LLC (TRC) | 2026-03-31 | 4,068 | Not shown | SEC filing |
| TWO SIGMA INVESTMENTS, LP | 2026-03-31 | 2,036,692 | Not shown | SEC filing |
| Stonepine Capital Management, LLC | 2026-03-31 | 100,000 | Not shown | SEC filing |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2026-03-31 | 516,182 | Not shown | SEC filing |
| Siren, L.L.C. | 2026-03-31 | 8,497,822 | Not shown | SEC filing |
| Virtu Financial LLC | 2026-03-31 | 25,489 | Not shown | SEC filing |
| SkyOak Wealth, LLC | 2026-03-31 | 150,000 | Not shown | SEC filing |
| Bank of New York Mellon Corp | 2026-03-31 | 39,182 | Not shown | SEC filing |
- Each value is checked against Neumora Therapeutics, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 20 rows: no share price from within three months of their report dates is on file, so they could not be checked.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- Invesco Ltd.: 227,594 shares reported 2025-12-31; 205,929 shares reported 2026-03-31.
- CITIGROUP INC: 43,832 shares reported 2025-12-31; 48,793 shares reported 2026-03-31.
- NISA INVESTMENT ADVISORS, LLC: 1,466 shares reported 2025-12-31; 1,466 shares reported 2026-03-31.
- UBS Group AG: 94,906 shares reported 2025-12-31; 59,584 shares reported 2026-03-31.
- AMERICAN CENTURY COMPANIES INC: 38,837 shares reported 2025-12-31; 39,810 shares reported 2026-03-31.
- MIC Capital Management UK LLP: 4,460,700 shares reported 2025-12-31; 4,460,700 shares reported 2026-03-31.
- RHUMBLINE ADVISERS: 2,581 shares reported 2025-12-31; 2,581 shares reported 2026-03-31.
- AlphaCore Capital LLC: 638,784 shares reported 2025-12-31; 638,784 shares reported 2026-03-31.
- SkyOak Wealth, LLC: 100,000 shares reported 2025-12-31; 150,000 shares reported 2026-03-31.
- GOLDMAN SACHS GROUP INC: 858,502 shares reported 2025-12-31; 568,280 shares reported 2026-03-31.
100 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Neumora Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-11-11 · Aurora Daljit Singh: Larger than all 20 other insider sales of Common Stock on file. SEC filing
- 2024-09-12 · Lenz Robert A.: Larger than 19 of the 20 other insider sales of Common Stock on file. SEC filing
- 2024-08-26 · Pinto Joshua: Larger than 18 of the 20 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2025-10-27–2025-10-27: 3 event(s) across 3 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing )
- 2023-11-08–2023-11-14: 11 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing , filing , filing , filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-02-17 | Aurora Daljit Singh · See Remarks | Common Stock | S — Open market or private sale | −6,165 | 3.56 | SEC filing |
| 2026-02-17 | Milligan Michael Lee · See Remarks | Common Stock | S — Open market or private sale | −1,436 | 3.57 | SEC filing |
| 2026-02-17 | BERNS PAUL L · See Remarks | Common Stock | S — Open market or private sale | −9,819 | 3.51 | SEC filing |
| 2026-02-17 | Pinto Joshua · President | Common Stock | S — Open market or private sale | −5,967 | 3.54 | SEC filing |
| 2025-11-11 | Aurora Daljit Singh · See Remarks | Common Stock | S — Open market or private sale | −114,703 | 2.68 | SEC filing |
| 2025-10-27 | ARCH Venture Fund VII, L.P. · 10% owner | Common Stock | P — Open market or private purchase | +1,915,700 | 2.61 | SEC filing |
| 2025-10-27 | Burow Kristina · Director, 10% owner | Common Stock | P — Open market or private purchase | +1,915,700 | 2.61 | SEC filing |
| 2025-10-27 | CRANDELL KEITH · 10% owner | Common Stock | P — Open market or private purchase | +1,915,700 | 2.61 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-05-27 | Halawa Alaa · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +80,000 | SEC filing |
| 2026-05-27 | Fust Matthew K · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +80,000 | SEC filing |
| 2026-05-27 | Piacquad David · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +80,000 | SEC filing |
| 2026-05-27 | Ho Maykin · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +80,000 | SEC filing |
| 2026-05-27 | Burow Kristina · Director, 10% owner | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +80,000 | SEC filing |
| 2026-01-08 | Aurora Daljit Singh · See Remarks | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +750,000 | SEC filing |
| 2026-01-08 | Pinto Joshua · President | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +1,200,000 | SEC filing |
| 2026-01-08 | Duncan Jason · See Remarks | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +750,000 | SEC filing |
Showing 8 of 30 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-05-28 | Ho Maykin · Director | Stock Option (Right to Buy) | D — Disposition to the issuer | −95,586 | SEC filing |
| 2025-05-28 | Duncan Jason · See Remarks | Stock Option (Right to Buy) | D — Disposition to the issuer | −400,000 | SEC filing |
| 2025-05-28 | Pinto Joshua · President | Stock Option (Right to Buy) | D — Disposition to the issuer | −720,084 | SEC filing |
| 2025-05-28 | Piacquad David · Director | Stock Option (Right to Buy) | D — Disposition to the issuer | −46,455 | SEC filing |
| 2025-05-28 | Halawa Alaa · Director | Stock Option (Right to Buy) | D — Disposition to the issuer | −46,455 | SEC filing |
| 2025-05-28 | Halawa Alaa · Director | Stock Option (Right to Buy) | D — Disposition to the issuer | −28,571 | SEC filing |
| 2025-05-28 | Aurora Daljit Singh · See Remarks | Stock Option (Right to Buy) | D — Disposition to the issuer | −136,210 | SEC filing |
| 2025-05-28 | Pinto Joshua · President | Stock Option (Right to Buy) | D — Disposition to the issuer | −3,000,000 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.